iScience (Sep 2022)

Heterotypic cell-in-cell structures between cancer and NK cells are associated with enhanced anticancer drug resistance

  • Yun-Jeong Choe,
  • Jin Young Min,
  • Hyunseong Lee,
  • Sang-Yeop Lee,
  • Joseph Kwon,
  • Hye-Jin Kim,
  • Jangho Lee,
  • Hyun Min Kim,
  • Hye Sun Park,
  • Mi Young Cho,
  • Ju-Yong Hyun,
  • Hye Min Kim,
  • Yong-Ho Chung,
  • Sang Keun Ha,
  • Hye Gwang Jeong,
  • Inpyo Choi,
  • Tae-Don Kim,
  • Kwan Soo Hong,
  • Eun Hee Han

Journal volume & issue
Vol. 25, no. 9
p. 105017

Abstract

Read online

Summary: The heterotypic CIC structures formed of cancer and immune cells have been observed in tumor tissues. We aimed to assess the feasibility of using heterotypic CICs as a functional biomarker to predict NK susceptibility and drug resistance. The heterotypic CIC-forming cancer cells showed a lower response to NK cytotoxicity and higher proliferative ability than non-CIC cancer cells. After treatment with anticancer drugs, cancer cells that formed heterotypic CICs showed a higher resistance to anticancer drugs than non-CIC cancer cells. We also observed the formation of more CIC structures in cancer cells treated with anticancer drugs than in the non-treated group. Our results confirm the association between heterotypic CIC structures and anticancer drug resistance in CICs formed from NK and cancer cells. These results suggest a mechanism underlying immune evasion in heterotypic CIC cancer cells and provide insights into the anticancer drug resistance of cancer cells.

Keywords